Startseite>>Signaling Pathways>> Immunology/Inflammation>> Immunotherapeutics>>SS-208

SS-208

Katalog-Nr.GC46226

SS-208 ist ein selektiver HDAC6-Inhibitor mit einem IC50 von 12 nM. SS-208 besitzt Anti-Tumor-AktivitÄt bei Melanomen.

Products are for research use only. Not for human use. We do not sell to patients.

SS-208 Chemische Struktur

Cas No.: 2245942-72-5

Größe Preis Lagerbestand Menge
5mg
296,00 $
Auf Lager
10mg
489,00 $
Auf Lager
25mg
918,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SS-208 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 12 nM).1 It is selective for HDAC6 over HDAC1, -4, -5, -7, -8, -9, and -11 (IC50s = 1.39, 19.5, 6.91, 8.34, 1.23, 38.2, and 5.12 μM, respectively). SS-208 (0.1-25 μM) inhibits HDAC6 in, but does not induce cell death of, human PC3 prostate, 5637 and T24 bladder, and murine SM1 melanoma cells in vitro. It decreases protein levels of programmed death ligand 1 (PD-L1) in SM1 cells when used at a concentration of 5 μM. SS-208 (25 mg/kg, i.p.) reduces tumor growth and increases the number of intratumoral CD8+, CD4+, and natural killer (NK) T cells in an SM1 murine melanoma model.

|1. Shen, S., Hadley, M., Ustinova, K., et al. Discovery of a new isoxazole-3-hydroxamate-based histone deacetylase 6 inhibitor SS-208 with antitumor activity in syngeneic melanoma mouse models. J. Med. Chem. 62(18), 8557-8577 (2019).

Bewertungen

Review for SS-208

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SS-208

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.